Auxilium Pharma to market Stendra for Erectile Dysfunction in the US and Canada
Vivus, Inc. has announced the signing of an agreement providing Auxilium Pharmaceuticals, Inc. the exclusive rights to market Stendra (avanafil) in the United States and Canada. The parties also simultaneously signed a Commercial Supply Agreement pursuant to which Vivus will be responsible for the manufacture and supply of Stendra to Auxilium for a mutually agreed term.
Stendra is an oral therapy approved by the FDA for the treatment of Erectile Dysfunction (ED). Under the license agreement, Vivus is eligible to receive up to $300 million based on certain regulatory and sales milestones, including an upfront licensing fee of $30 million and a $15 million payment contingent upon a potential label amendment regarding onset-of-action, in addition to royalties on product sales.
Auxilium expects to begin its commercial launch of Stendra by the end of 2013, first with shipments of Stendra in December 2013, followed by promotional activities in early January 2014 with its PRIMERA sales force.
Related news and insights
The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Cevenfacta, intended for the treatment of bleeding episodes.
Calliditas Therapeutics announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the granting of a conditional marketing authorisation for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) greater than 1.5 g/gram.